{
    "nct_id": "NCT05948943",
    "official_title": "A Two-stage Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.",
    "inclusion_criteria": "* Participant must be willing to remain at the clinical site as required by the protocol and be willing to adhere to study restrictions and examination schedules.\n* Participant has a physician confirmed and documented diagnosis of a LyM at the time of informed consent\n* Participant is not considered as a candidate for or is not willing to receive local therapy options including but not limited to sclerotherapy, embolization, and surgery until the completion of Week 24 in Stage 1 and 2.\n* Participant has evidence of a somatic mutation(s) in the PIK3CA gene\n* Participant has at least one measurable LyM lesion confirmed by BIRC assessment prior to randomization.\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 2 Years",
    "exclusion_criteria": "* Participant has a physician-confirmed and documented diagnosis of PROS at the time of informed consent.\n* Participant has a physician-confirmed and documented diagnosis of a Central Conducting Lymphatic Anomaly, General Lymphatic Anomaly, Gorham-Stout disease, Kaposiform lymphangiomatosis at the time of informed consent.\n* Participant has a known history of Stevens-Johnson syndrome, erythema multiforme, or toxic epidermal necrolysis at the time of informed consent.\n* Participant has an established diagnosis of type I diabetes mellitus or uncontrolled type II diabetes mellitus at the time of informed consent.\n* Participant had previous treatment with alpelisib and/or any other PI3K inhibitors with treatment duration longer than 2 weeks at the time of informed consent.\n\nOther inclusion/exclusion criteria may apply",
    "miscellaneous_criteria": "Key"
}